Drug resistance is a major challenge in cancer treatment. Emerging evidence indicates that
deregulation of YAP/TAZ signaling may be a major mechanism of intrinsic and acquired …

ABSTRACT YAP and TAZ proteins are transcriptional coactivators encoded by paralogous
genes, which shuttle between the cytoplasm and the nucleus in response to multiple inputs …

The Hippo pathway, initially identified through screenings for mutant tumor suppressors in
Drosophila, is an evolutionarily conserved signaling pathway that controls organ size by …

Highlights•YAP/TAZ are activated in a broad number of solid tumors.•YAP/TAZ instrumental
for tumor initiation, growth, metastasis and chemoresistance.•Several inputs control …

A diverse range of drug resistance mechanisms in cancer cells and their microenvironment
significantly reduces the effectiveness of anti-cancer therapies. Growing evidence suggests …

The activation of transcriptional coactivators YAP and its paralog TAZ has been shown to
promote resistance to anti‐cancer therapies. YAP/TAZ activity is tightly coupled to actin …

Yes-Associated Protein (YAP) and Transcriptional Co-activator with PDZ-binding Motif (TAZ)
have both emerged as important drivers of cancer progression and metastasis. YAP and …

The transcriptional co-regulators YAP and TAZ pair primarily with the TEAD family of
transcription factors to elicit a gene expression signature that plays a prominent role in …

Hippo signaling was first identified in Drosophila as a key controller of organ size by
regulating cell proliferation and anti-apoptosis. Subsequent studies have shown that this …

YAP and TAZ oncoproteins confer malignancy and drug resistance to various cancer types.
We screened for small molecules that inhibit the nuclear localization of YAP/TAZ. Dasatinib …